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Ventilator-associated pneumonia (VAP) is one of the most common hospital-associated infections and 
has accounted for approximately 15% of all hospital-associated infections. In 76% of the VAP cases, the 
same bacteria colonize the oral cavity and lungs. Oral care interventions may play a role in the 
prevention of VAP, yet more than half of the hospitals do not have specific policies for the oral care of 
intubated patients. Oral cavity interlinks with respiratory tracts and digestive tracts. After surgery has 
been performed in these areas, aerobic and anaerobic bacteria frequently induce operative wound 
infections in teeth, gingiva and supporting tissues of the teeth and tonsils. This study investigates the 
effects of a nanotechnology antimicrobial spray (JUC) on the incidence of VAP. 320 patients diagnosed 
with VAP were randomly divided into treatment and control groups. After using chlorhexidine 
mouthrinse, the treatment group used a nanotechnology antimicrobial spray to the nose and mouth. 
The control group was given normal saline. The incidence rate of VAP was significantly lower in the 
treatment (8.38%) than control group (54.24%) (p<0.01). A physical antimicrobial film is formed on the 
surface of oral and nasal mucosa after using the JUC spray which effectively reduces the microbial 
colonization in the sprayed areas, thus reducing and delaying the incidence of VAP. 
 
Key words: Ventilator-associated pneumonia, oral care, nanotechnology antimicrobial spray, bacterial 
colonization. 
 
 
INTRODUCTION 
 
Ventilator-associated pneumonia (VAP) is one of the most 
common hospital-associated infections and has accoun-
ted for approximately 15% of all hospital-associated 
infections. It has been the second most common hospital-
associated infection following its occurrence in the urinary 
tract, for which the  mortality  ranges  from  1  to  4%.  The 
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Abbreviations: VAP, Ventilator-associated pneumonia; WBC, 
white blood cell; CFU, colony formation unit; BAL, 
bronchoalveolar lavage; CPIS, clinical pulmonary infection 
score; ICU, intensive care unit.  
mortality rate for VAP which is defined as pneumonia 
occurring more than 48 h after endotracheal intubation 
and initiation of mechanical ventilation, ranges from 24 to 
50% and can reach 76% in some specific settings or 
when lung infection is caused by high-risk pathogens 
(U.S. Department Of Health And Human Services Public 
Health Service Centers for Disease Control, 1997; Haley 
et al., 1981; Centers for Disease Control and Prevention, 
2000; National Nosocomial Infections Surveillance 
(NNIS) System, 1999; Bell et al., 1983; Celis et al., 1988; 
Chastre et al., 1998; Chevret et al., 1993; Craven et al., 
1986; Craven and Steger, 1996; Cross and Roup, 1981; 
Delclaux et al., 1997; Fagon et al., 1989; Haley et al., 
1981; Langer et al., 1989; Markowicz et al., 2000; Rello 
et al., 1993; Rello et al., 1997; Torres et al., 1990; Vincent  
  
 
 
et al., 1995). VAP is the most common infectious 
complication among patients admitted to intensive care 
units (ICUs) and accounts for up to 47% of all infections 
among ICU patients (Charitos et al., 2009; Leroy et al., 
2001). ICU patients are at high risk of infection with 
Staphylococcus aureus, whereas Haemophilus influenzae 
and Streptococcus pneumoniae usually dominate in 
postsurgical trauma patients. VAP prolongs ICU’s stay 
and increases treatment costs as well as the risk of death 
in critically ill patients (Carolyn et al., 2007; Chevret et al., 
1993; Vincent et al., 1995). In 76% of the VAP cases, the 
same bacteria colonize the oral cavity and lungs (Chastre 
and Fagon, 2002; Doré et al., 1996). Oral care interven-
tions may play a role in the prevention of VAP, yet more 
than half of the hospitals do not have specific policies for 
the oral care of intubated patients (Carolyn et al., 2007; 
Doré et al., 1996; Marra et al., 2009). Oral cavity inter-
links with respiratory tracts and digestive tracts. After 
surgery has been performed in these areas, aerobic and 
anaerobic bacteria frequently induce operative wound 
infections in teeth, gingiva and supporting tissues of the 
teeth, tonsils, etc. (Salam et al., 2001; Senpuku et al., 
2002; 2006). These infected areas generally offer bene-
ficial environment, i.e. suitable temperature and humidity 
for bacterial proliferation leading to frequent infections. 
In general, infections are commonly found in oral 
cancer patients after surgical excision of the tumor 
(Senpuku et al., 2003; Senpuku et al., 2006; Tada and 
Tanzawa, 2002; Tada et al., 2002; Zeng et al., 2008). This 
could be due to exposure of wounds during and after the 
operation. Patients, who received oral surgery often 
appear to have complications relating to bacterial infec-
tions. Colonization of pathogenic bacteria in oral cavity is 
thought to increase the risk of infections such as 
pneumonia and bacteremia (Costerton and Greenberg, 
1999; Gosney et al., 1999). Therefore, it is of high impor-
tance to prevent bacteria from entering the lungs orally or 
nasally. 
Currently, the systemic applications of antibacterial 
drugs have shown better results in curing diseases than 
local application, which may induce drug-resistant bac-
teria in the particular area (Belusic-Gobic et al., 2007; 
Cloke et al., 2004). A nanotechnology antimicrobial spray, 
JUC, physical antimicrobial dressing was applied to some 
affected areas of oral cancer patients after surgery and 
proved to be a new physical antimicrobial method that 
does not have the tendency to lead to drug resistance 
(Zeng et al., 2008).  
In this study, JUC spray was applied to the oral and 
nasal cavities of intubated patients in ICU to compare the 
incidence of VAP with conventional oral care. 
 
 
MATERIALS AND METHODS 
 
Actions and the quality control of JUC 
 
The antimicrobial effect and quality of JUC spray were monitored 
and controlled by  NMS  Technologies  Company  (Nanjing,  China). 
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When water-soluble liquid of JUC was sprayed on skin surfaces or 
mucosal areas, it immediately solidifies and forms an invisible anti-
microbial layer with dual overlapping structure; the bonded film and 
the positive charge film. The bonded film is composed of macro-
molecular agents, securely boned to the body surface by means of 
chemical bonds. This bonded film has a long acting effect to 
prevent microbial growth. The positive charge film is composed of 
cationic activators to form a reticulate film with positive charge of 
the skin surface or mucosal area. The positive film strongly absorbs 
the pathogenic microorganism with a negative charge, such as bac-
teria, fungi, and viruses. If the pathogenic microorganisms’ 
respiratory enzyme on which they rely for existence is out of action, 
they will die due to a lack of oxygen supply (Zeng et al., 2008). 
This spray had been tested by Food & Drug Analytical Services 
Limited (Approval no: 9083481, USA) against Acinetobacter 
baumanii on a range of surfaces. JUC had passed all the tests on 
floor, metal handle, perspex, plastic handle and steel surfaces. Also, 
JUC had been tested by the University of New Brunswick (CE 
approval No: 153038905) on the zeta potential and hydrodynamic 
size of the dress sample. JUC demonstrated high zeta-potential 
values over a broad range of pH and the hydrodynamic size of the 
sample was 2.57nm in 0.5% aqueous solution. 
 
 
Selection of subjects 
 
From January 2009 to March 2010, 320 ICU patients requiring mec-
hanical ventilation were recruited from Shenzhen People’s Hospital. 
Each patient was numbered and those of odd numbers were 
assigned to the treatment group (167 cases) and even-numbered 
were the control group (153 cases). Patients satisfying the following 
conditions were excluded: Under 18 years of age, history of using 
mechanical ventilation, pregnancy or lactating, pneumonia, bron-
chiectasis, hemoptysis, pulmonary cyst or pulmonary fibrosis 
(Munro et al., 2009). Both treatment and control groups had teeth, 
oral mucosa, tongue and palate cleansed by chlorohexidine mouth-
rinse every 8 h, 3 times daily for 5 days. Suction of 0.2 bar was 
used to withdraw mouthrinse from patients’ mouth. The treatment 
group was sprayed with JUC spray orally and nasally after 
mouthrinse. The studied protocols were approved by the Ethics 
Committee of Shenzhen People’s Hospital.  
 
 
Sample Collection 
 
Tracheal secretion together with oral, nasal and throat swabs of the 
patients were collected every 4 h for 5 days for bacterial culture and 
identification after 24 h of intubation. Deep sputum samples were 
collected by protected specimen brush under bronchoscopy. 
 
 
Criteria for diagnosis of VAP 
 
The diagnosis of VAP must include persistent radiographic 
infiltration over 48 h, temperature over 38.5°C, total white blood cell 
(WBC) count 10×109/L  and colony formation unit (CFU) test 
results over 103cfu/ml on protected specimen brush or broncho-
alveolar lavage (BAL) fluid over 104cfu/ml (Elie et al., 2006). 
According to the onset time, there are two clinical types of VAP, the 
early and late-onset VAP. The early-onset VAP is pneumonia that 
occurred within 48-96 h after intubation and mechanical ventilation 
while the late-onset VAP occurred more than 96 h after mechanical 
ventilation (Qinhua and Lixian, 2004). 
 
 
Statistical analysis 
 
The SPSS 11.0 software package was used to collect  and  analyze  
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Table 1. General information of 320 patients ( ±s). 
 
Parameter Treatment group (n=167) Control group (n=153) t  value p  value 
Age(years) 57.4 ±15.2 55.1 ±14.8 1.371 >0.05 
Observation days 8.41 ±2.10 8.27 ±2.07 0.596 >0.05 
APACHE ii score. 21.62 ±6.78 22.47 ±6.27 1.164 >0.05 
CPIS scores 3.85 ±1.58 4.03 ±1.62 1.006 >0.05 
 
 
 
Table 2. Incidence of early-onset VAP patients. 
 
Group Number of cases Incidence VAP (%) X2 p value Early-onset VAP (%) X2 p value 
Control 153 83 (54.24) 79.51 42 (50.60) 46.41 
Treatment 167 14 (8.38) p<0.01 2 (14.29) p<0.01 
 
 
 
Table 3. Pathogens found in pharynx oralis (strains).  
 
Group A B C D E F G H I J K Total strains 
Control 63 50 38 36 30 22 18 20 277* 22 25 324** 
Treatment 8 7 5 4 3 2 1 2 32* 2 3 37** 
 
A, Klebsiella pneumonia; B, Pseudomonas aeruginosa; C, Acinetobacter; D, Pseudomonas maltophilia; E, Escherichia coli; F, Enterobacter cloacae; 
G, Streptococcus pneumonia; H, Staphylococcus aureus; I, total number of VAP caused bacteria; J, Candida tropicalis; K,     Candida albicans. 
*Significant difference between both groups at P<0.01; **significant difference between the treatment group and the control group at P<0.01. 
 
 
 
the clinical data expressed as ±SD. The Q-test in analysis of 
variance was used to compare data between two groups. The t test 
in paired design was used to compare data collected at different 
time points within the groups. The rank test was used to compare 
the rate and constituent ratio of VAP. 
 
 
RESULTS AND DISCUSSION 
 
General information of patients 
 
There were no significant differences in age, gender, rea-
sons for ICU admission, acute physiology and chronic 
health evaluation (APACHE) II, clinical pulmonary infec-
tion score (CPIS) or days of admission to ICU between 
both groups prior to recruitment for this study (Table I).  
 
 
Incidence of VAP 
 
VAP occurred in 14 patients (8.38%) of the treatment 
group and 83 patients (54.24%) of the control group. 
Statistically, significant difference (p<0.01) was observed 
between the two groups (Table 2). Early-onset VAP was 
observed in 2 patients (14.29%) of the treatment group 
and 42 patients (50.60%) of the control group with signifi-
cant difference (p<0.01) (Table 2). 
Bacterial culture 
 
10 types of pathogens were collected from 320 patients. 
324 strains were isolated in the control group and 37 
strains in the treatment group. The isolated strains were 
mainly composed of Gram negative bacteria including 
Klebsiella pneumoniae, Pseudomonas aeruginosa and 
Acinetobacter. There were significant difference (p<0.01) 
between the two groups (Table 3). 
 
 
Deep sputum culture 
 
10 types of pathogens were cultured in 320 patients. 268 
strains were isolated in the control group and 33 strains 
in the treatment group. The sputum cultures were mainly 
composed of Klebsiella pneumoniae and pseudomonas 
aeruginosa with significant difference (p<0.01) between 
the groups (Table 4). 
 
 
Bacterial colonization rate  
 
There was statistically significant difference (p<0.01) bet-
ween two groups for endotracheal colonization less than 
96 h, while no difference was observed for over 96 h. The 
opposite is applied to  oropharyngeal  colonization  as  no  
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Table 4. Pathogens found in deep phlegm (strains). 
 
Group A B C D E F G H I J K Total strains 
Control 56 56 30 30 26 26 7 13 244* 14 10 268** 
Treatment 8 7 3 3 4 4 2 0 31* 2 0 33** 
 
A, Klebsiella pneumonia; B, Pseudomonas aeruginosa; C, Acinetobacter; D, Pseudomonas maltophilia; E, Escherichia coli; F, Enterobacter 
cloacae; G, Streptococcus pneumonia; H, Staphylococcus aureus; I, total number of VAP caused bacteria; J, Candida tropicalis; K,     Candida 
albicans.  
*Significant difference between both groups at P<0.01; **significant difference between the treatment group and the control group at P<0.01. 
 
 
 
Table 5. The rate of bacterial colonization in trachea and pharynx oralis between the two groups. 
 
Region Time of colony formation (h) 
Treatment group (n=167) Control group (n=153) 

2
 P value No. of 
cases 
Bacterial 
colonization (%) 
NO. of 
cases 
Bacterial 
colonization (%) 
Endotracheal <96h 4 2.40 5 3.27 0.22 P>0.05 
Mouth >96h 7 4.19 34 22.22 23.24 P<0.01 
Nose <96h 5 2.99 7 4.58 0.55 P>0.05 
Pharyngeal cavity >96h 8 4.79 50 32.68 41.85 P<0.01 
 
 
 
statistically significant difference exists between the two 
groups under 96 h, but there was significant difference 
(p<0.01) over 96 h (Table 5). 
VAP is defined as pneumonia in patients receiving 
mechanical ventilation and it is also a leading cause of 
sepsis with acute respiratory failure and a significant 
contributor to morbidity and mortality in intensive care unit 
patients (Leroy et al., 2001; Tejerina et al., 2010). During 
1992 to 2004, NNIS report reveals a median rate of VAP 
associated with mechanical ventilation to be 2.2 to 14.7 
cases per 1000 patients per day in adult ICUs. The 
estimated mortality rate is between 20 and 70% (Cuellar 
et al., 2004). 
 
VAP can be categorized into: 
 
Early-onset VAP (EOP) occurs during the first 4 days of 
trachea cannula and artificial airway establishment and 
accounts for 50% of VAP, most often caused by phary-
ngeal parasitic bacterium (such as Streptococcus 
pneumoniae, Haemophilus influenzae, Staphylococcus 
aureus).  
Late-onset VAP occurs at least 5 days after intubation 
and is most often caused by gram negative bacterium (for 
example, Enterobacter, Acinetobacter, and Pseudomonas 
aeruginosa) (Badia and Torres, 2008; Niederman and 
Craven, 2005; Diaz et al., 2009; Medford et al., 2009). 
There is a wide range of bacteria in the mouth, nose 
and pharynx, including various potential pathogenic bac-
teria. The barriers of these areas plus lower respiratory 
tract of patients receiving mechanical ventilation are 
directly destroyed. Transient pressure decreased by air 
sac, change in posture or airway diameter cause the 
secretion to pass to the lower respiratory tract through the 
gap between endotracheal wall and catheter (Marra et 
al., 2009). 
Contemporary oral hygiene for ICU patients mainly 
uses normal saline or chlorhexidine mouth rinse to clean 
the oral cavity but they have no or short term disinfection 
effect. Antibiotic solution may increase the risk of resis-
tance for pathogenic bacteria and is not recommended 
(Díaz et al., 2010). Many international scholars are 
exploring effective oral hygiene methods to reduce the 
incidence of VAP (Gastmeier and Geffers, 2007; Heyland 
et al., 2002; Keenan et al., 2002; Livingston, 2000). JUC 
Spray Dressing can provide the antimicrobial effect for 8 
h and produces no drug resistance, providing an inno-
vative solution to prevent the incidence of VAP. 
The mechanism of JUC in reducing the incidence rate 
of VAP by killing and inhibiting pathogenic microorganism 
by electrostatic force. JUC spray has little irritation to 
mucous membrane and does not cause drug resistance 
after long term usage. 
In this study, it was found that patients who had JUC 
spray applied to oral and nasal cavities had lower inci-
dence rates of VAP, the proportion of early-onset VAP 
and bacterial colonization in trachea, mouth, nose and 
pharyngeal portion was compared to the control group. 
JUC is a safe and effective physical antimicrobial spray 
dressing for mouth, nose and pharyngeal cavity. Although 
there was no significant difference in the incidence of 
bacterial colonization in mouth, nose, pharyngeal cavity 
and trachea between the two groups of early-onset VAP 
(<96h), the colonization rate of early onset VAP (<96h) in 
the treatment group was lower than that in the control 
group. 
JUC is a physical antimicrobial agent that can replace 
contemporary disinfectants for oral care and alleviate the 
setback of clinical drug resistance. It is a new method for 
preventing the incidence of VAP safely and effectively.  
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